View Older Stories View More Recent Stories

Mar 15, 2022 04:30PM Molecular Partners Reports Corporate Highlights From Q4 2021 and Key Financials for Full Year 2021
Feb 25, 2022 04:30PM Molecular Partners to Present at Upcoming Healthcare Investor Conferences
Feb 11, 2022 04:10PM Molecular Partners to Present at Upcoming Healthcare Investor Conference
Feb 10, 2022 04:41AM Molecular (MOLN) Announces Emergency Use Authorization Request for Ensovibep Submitted to the FDA
Feb 10, 2022 01:00AM Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of COVID-19
Jan 18, 2022 05:36AM Molecular Partners AG (MOLN) Enters Licensing Agreement with Novartis for Ensovibep for COVID-19
Jan 18, 2022 01:00AM Molecular Partners Finalizes License Agreement with Novartis for Ensovibep for COVID-19
Jan 13, 2022 05:00PM Molecular Partners Reports Disclosure of Major Shareholder as per Swiss Stock Exchange Regulations
Jan 10, 2022 05:35AM Molecular Partners AG (MOLN) and Novartis' Phase 2 Study of Ensovibe Met Primary Endpoint
Jan 10, 2022 01:17AM Molecular Partners and Novartis Report Positive Topline Data from Phase 2 Study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19
Jan 5, 2022 04:05PM Molecular Partners to Present at Upcoming Healthcare Investor Conferences
Dec 15, 2021 01:00AM Molecular Partners to Host Oncology Day (Virtual)
Dec 14, 2021 05:43AM Molecular Partners AG (MOLN) Collaborates with Novartis to Develop DARPin-Conjugated Radioligand Therapeutic Candidates for Oncology
Dec 14, 2021 01:00AM Molecular Partners Announces Collaboration with Novartis to Develop DARPin-Conjugated Radioligand Therapeutic Candidates for Oncology
Dec 13, 2021 05:04AM Molecular Partners AG (MOLN) Announces Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies
Dec 12, 2021 04:00PM Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies
Dec 9, 2021 01:00AM Molecular Partners Highlights Upcoming Oncology Portfolio Presentations in December
Dec 6, 2021 05:23AM Molecular Partners AG (MOLN) Reports Results from a Phase 2a Trial of Ensovibep in 12 COVID-19 Patients
Dec 6, 2021 01:00AM Molecular Partners Presents Results from a Phase 2a Trial of Ensovibep in 12 COVID-19 Patients at ESWI 2021
Dec 3, 2021 01:00AM Molecular Partners Announces Research Collaboration with University of Bern to Develop MP0533, a Multispecific DARPin for the Treatment of AML
Nov 30, 2021 01:00AM Molecular Partners Confirms Retained Activity of Ensovibep on the Positions Mutated in Emerging Omicron Variant of SARS-CoV-2 In Vitro
Nov 24, 2021 01:00AM Molecular Partners Announces Presentation at the Evercore ISI 4th Annual HealthCONx Conference
Nov 16, 2021 05:51AM Molecular Partners AG (MOLN) Announces Analysis From ACTIV-3 Study of Ensovibep Did Not Meet Thresholds to Continue Enrollment
Nov 16, 2021 01:00AM Molecular Partners Provides Update from ACTIV-3 Global Clinical Study of Ensovibep in Patients Hospitalized with COVID-19
Nov 4, 2021 02:00AM Molecular Partners Announces First Patient Dosed with CD40 Therapeutic Candidate MP0317 in Phase 1 Clinical Trial
Oct 28, 2021 05:32AM Molecular Partners AG (MOLN) Issues Clinical Development Updates
Oct 28, 2021 01:00AM Interim Management Statement Q3 2021 of Molecular Partners: Advancement of COVID-19 Clinical Program and Continued Immuno-Oncology Momentum
Oct 20, 2021 05:46AM Molecular Partners AG (MOLN) Reports Data Demonstrating Successful Inhibition of COVID19 Viral Variants with Ensovibep
Oct 20, 2021 01:00AM Molecular Partners Present Data Demonstrating Successful Inhibition of COVID19 Viral Variants with Ensovibep at the 2021 ISIRV-WHO Conference
Sep 3, 2021 04:05PM Molecular Partners to Present at Upcoming Healthcare Investor Conferences
Aug 26, 2021 01:00AM Molecular Partners Reports Corporate Highlights and Key Financials for H1 2021
Aug 9, 2021 01:00AM Molecular Partners to Regain Global Rights to Abicipar
Jul 8, 2021 01:00AM Molecular Partners Reports Continued Progress of Ensovibep Global Clinical Program; Positive in vitro Data Demonstrating Maintained Inhibition of Delta and All Other Known Variants of Concern of SARS-
Sep 18, 2019 01:00PM Divide & Conquer, Developing New Class of Cancer Therapeutics to Disrupt Cell-to-Cell Communication, Emerges from Stealth as New Paper by Co-Founder is Published in Nature
Dec 18, 2018 11:00PM Amgen And Molecular Partners Announce Strategic Collaboration In Immuno-Oncology
View More Recent Stories View Older Stories